在卵巢癌患者中使用CA 125监测异维甲酸和骨化三醇的试验。
Trial of isotretinoin and calcitriol monitored by CA 125 in patients with ovarian cancer.
作者信息
Rustin G J, Quinnell T G, Johnson J, Clarke H, Nelstrop A E, Bollag W
机构信息
Department of Medical Oncology, Mount Vernon Centre for Cancer Treatment, Mount Vernon Hospital, Northwood, Middlesex, UK.
出版信息
Br J Cancer. 1996 Nov;74(9):1479-81. doi: 10.1038/bjc.1996.568.
Abstract
Twenty-two asymptomatic women with rising CA 125 levels after chemotherapy for ovarian cancer were entered into a trial of isotretinoin combined with calcitriol. Tumours were evaluated according to precise criteria based on serial CA 125 levels and by comparing regression slopes of CA 125 before and during therapy. There was no evidence based on CA 125 of any responses or significant change in tumour growth rate.
摘要
22名卵巢癌化疗后CA 125水平升高的无症状女性参加了异维A酸联合骨化三醇的试验。根据基于连续CA 125水平的精确标准并通过比较治疗前和治疗期间CA 125的回归斜率对肿瘤进行评估。基于CA 125没有证据表明有任何反应或肿瘤生长速率有显著变化。
相似文献
1
Trial of isotretinoin and calcitriol monitored by CA 125 in patients with ovarian cancer.在卵巢癌患者中使用CA 125监测异维甲酸和骨化三醇的试验。
Br J Cancer. 1996 Nov;74(9):1479-81. doi: 10.1038/bjc.1996.568.
2
Prognostic significance of rising serum CA-125 levels within the normal range in patients with epithelial ovarian, primary peritoneal, and tubal cancers, who, after initial treatment, had a complete clinical response.在初始治疗后获得完全临床缓解的上皮性卵巢癌、原发性腹膜癌和输卵管癌患者中，血清 CA-125 水平在正常范围内升高的预后意义。
Int J Gynecol Cancer. 2012 Oct;22(8):1344-8. doi: 10.1097/IGC.0b013e3182691254.
3
The prognostic value of pretreatment CA-125 levels and CA-125 normalization in ovarian clear cell carcinoma: a two-academic-institute study.术前CA-125水平及CA-125正常化在卵巢透明细胞癌中的预后价值：一项双学术机构研究
Oncotarget. 2016 Mar 29;7(13):15566-76. doi: 10.18632/oncotarget.7216.
4
CA-125 criteria for response evaluation in ovarian cancer.卵巢癌反应评估的CA - 125标准。
Gynecol Oncol. 2005 Sep;98(3):520-1. doi: 10.1016/j.ygyno.2005.07.021.
5
Evaluation of various kinetic parameters of CA-125 in patients with advanced-stage ovarian cancer undergoing neoadjuvant chemotherapy.评价接受新辅助化疗的晚期卵巢癌患者 CA-125 的各种动力学参数。
PLoS One. 2018 Sep 6;13(9):e0203366. doi: 10.1371/journal.pone.0203366. eCollection 2018.
6
Platelet-derived growth factor receptor beta serum concentrations during first-line therapy in ovarian cancer.卵巢癌一线治疗期间血小板衍生生长因子受体β血清浓度。
Oncology. 2013;85(2):69-77. doi: 10.1159/000351032. Epub 2013 Jul 16.
7
CA 125 regression after two completed cycles of chemotherapy: lack of prediction for long-term survival in patients with advanced ovarian cancer.两个化疗周期完成后CA 125的下降：对晚期卵巢癌患者长期生存缺乏预测价值
Br J Cancer. 1999 Oct;81(4):662-6. doi: 10.1038/sj.bjc.6690744.
8
Possible use of CA-125 level normalization after the third chemotherapy cycle in deciding on chemotherapy regimen in patients with epithelial ovarian cancer: brief report.上皮性卵巢癌患者第三次化疗周期后 CA-125 水平正常化对化疗方案选择的可能作用：简短报告。
Int J Gynecol Cancer. 2011 Aug;21(6):1013-7. doi: 10.1097/IGC.0b013e31821ce903.
9
Chemotherapy-induced changes of CA 125 in patients with epithelial ovarian cancer.上皮性卵巢癌患者化疗引起的CA 125变化
Gynecol Oncol. 2005 May;97(2):410-2. doi: 10.1016/j.ygyno.2005.02.003.
10
Use of CA 125 in follow-up of ovarian cancer.CA 125在卵巢癌随访中的应用。
Lancet. 1996 Jul 20;348(9021):191-2. doi: 10.1016/s0140-6736(05)66133-8.
引用本文的文献
1
The impact of novel retinoids in combination with platinum chemotherapy on ovarian cancer stem cells.新型维甲酸联合铂类化疗对卵巢癌干细胞的影响。
Gynecol Oncol. 2012 Apr;125(1):226-30. doi: 10.1016/j.ygyno.2011.12.425. Epub 2011 Dec 9.
本文引用的文献
1
Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study.根据CA 125定义卵巢癌随访期间的进展：北泰晤士卵巢组研究
Ann Oncol. 1996 Apr;7(4):361-4. doi: 10.1093/oxfordjournals.annonc.a010602.
2
Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125.根据血清CA 125定义卵巢癌对初始化疗的反应。
J Clin Oncol. 1996 May;14(5):1545-51. doi: 10.1200/JCO.1996.14.5.1545.
3
Response of four human ovarian carcinoma cell lines to all-trans retinoic acid: relationship with induction of differentiation and retinoic acid receptor expression.四种人卵巢癌细胞系对全反式维甲酸的反应：与分化诱导及维甲酸受体表达的关系
Int J Cancer. 1994 Mar 1;56(5):743-8. doi: 10.1002/ijc.2910560522.
4
Combination of isotretinoin and calcitriol for precancerous and cancerous skin lesions.异维A酸与骨化三醇联合用于癌前及癌性皮肤病变
Lancet. 1994 Nov 26;344(8935):1510-1. doi: 10.1016/s0140-6736(94)90330-1.
5
Remission of cutaneous T-cell lymphoma with combined calcitriol and acitretin.
Lancet. 1994 Sep 3;344(8923):686-7. doi: 10.1016/s0140-6736(94)92122-9.
6
Cutaneous T-cell lymphoma and calcitriol and isotretinoin treatment.皮肤T细胞淋巴瘤与骨化三醇及异维A酸治疗
Lancet. 1995 Jun 17;345(8964):1583. doi: 10.1016/s0140-6736(95)91137-5.
7
The role of CA 125 in the early diagnosis of progressive disease in ovarian cancer.CA 125在卵巢癌疾病进展早期诊断中的作用。
Ann Oncol. 1990 Jul;1(4):301-2. doi: 10.1093/oxfordjournals.annonc.a057754.
8
Alfacalcidol is a nontoxic, effective treatment of follicular small-cleaved cell lymphoma.
Br J Cancer. 1991 Mar;63(3):463-5. doi: 10.1038/bjc.1991.108.
9
13-cis-retinoic acid plus interferon alpha-2a: highly active systemic therapy for squamous cell carcinoma of the cervix.
J Natl Cancer Inst. 1992 Feb 19;84(4):241-5. doi: 10.1093/jnci/84.4.241.
10
Topical calcipotriol treatment in advanced breast cancer.外用卡泊三醇治疗晚期乳腺癌。
Lancet. 1991 Mar 23;337(8743):701-2. doi: 10.1016/0140-6736(91)90280-3.
Zotero 插件